Topic
Retatrutide
10 stories related to this topic, newest first.
Statscience6 days ago
Eli Lilly grants one patient access to obesity drug candidate via FDA program
Eli Lilly and the Food and Drug Administration approved compassionate-use access to retatrutide for a single individual. The decision was discussed on a weekly biotech podcast alongside topics of drug acquisitions and hair-loss treatments.
benzinga.comscience8 days ago
Eli Lilly Provided Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
STAT reported that Eli Lilly supplied its experimental obesity drug retatrutide to a single 79-year-old man via the FDA’s compassionate-use pathway in April. The access drew attention from top health officials. Three sources requested anonymity citing fear of reprisals.
benzinga.comscience8 days ago
Eli Lilly Supplied Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
Stat reported that Eli Lilly supplied its experimental drug retatrutide to a single patient through the FDA’s compassionate-use pathway in April. The request involved a 79-year-old man and drew attention from senior health officials. Retatrutide has produced substantial weight lo…
cnbc.comscience25 days ago
Retatrutide Shows Strong Blood-Sugar and Weight-Loss Benefits in Diabetes Trial With Limited Cardiac Events
New safety figures from Eli Lilly’s TRANSCEND-T2D-1 study were released Saturday at the American Diabetes Association meeting and published in the Lancet.
/cdn.vox-cdn.com/uploads/chorus_asset/file/24856972/236744_Withings_Body_Smart_VSong_0003.jpg)
theverge.comscience33 days ago
Retatrutide Shows 28 Percent Body Weight Reduction in Trials
Retatrutide, a triple-receptor drug targeting GLP-1, GIP, and glucagon, produced the largest average weight loss reported so far. The medication also carries additional safety considerations.
ER
finance.yahoo.comscience40 days ago
Eli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
Nbc Newsworld41 days ago
Eli Lilly Weight Loss Drug Retatrutide Shows Up to 30 Percent Body Weight Loss in Trial
Eli Lilly reported that its experimental drug retatrutide produced average weight loss of 28 percent after 80 weeks and up to 85 pounds in some patients. The results come from a phase 3 trial of roughly 2,300 people and remain comparable to outcomes from bariatric surgery.
benzinga.comscience41 days ago
Eli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.
Substrate placeholder — needs reviewscience84 days ago
Andrew Huberman Notes Women's Role in Peptide Market and Audience Interest
Neuroscientist Andrew Huberman stated that women form a significant part of the peptide market, particularly in sharing GLP and Retatrutide products. He mentioned that about 45% of his Huberman Lab Podcast listenership is female. Huberman receives frequent questions from female l…
HU
Substrate placeholder — needs reviewscience86 days ago
Rise in Testing of Unregulated Peptides in UK Amid Weight-Loss and Wellness Demand
Laboratories in the UK and internationally are processing thousands of samples of unregulated peptides sent by consumers for quality verification. These substances, often marketed for weight loss, biohacking, and anti-aging, include experimental compounds like retatrutide, which…